Off-market insider buying at StageZero Life Sciences (T:SZLS)

Rory Riggs, a Director and 10% Holder, acquired 7,608,967 Common Shares on a direct ownership basis at a price of $0.070 through a prospectus or prospectus exempt offering on July 6th, 2020. The insider also acquired 7,608,967 Warrants with an exercise price of $0.090 at any time prior to June 29, 2023. This represents a $532,628 investment into the company's shares and an account share holdings change of greater than 100%.

StageZero Life Sciences is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

StageZero Life Sciences Ltd. is a Canada-based company focused on developing and commercializing molecular diagnostic tests for early detection of cancer. It has developed Sentinel Principle platform technology, which determines biomarkers from whole blood. In additional, the Company offers ColonSentry product, it is a blood test to determine an individual's current risk for having colorectal cancer. It is developing cancer testing kit Aristotle, which is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood. The Company is also focused on testing Aristotle application on other disease conditions including neurology, gastroenterology, cardiology, and autoimmune disorders.